Wide Scale Testing Beginning for COVID-19 Vaccines

Researchers are making so much progress in developing a vaccine against COVID-19 that the first wide-scale testing could begin in a matter of weeks.

The New York Times Coronavirus Vaccine Tracker says a vaccine developed by the 10-year-old biotech company Moderna expects to start wide-scale testing this month. If it does, it would mark an almost unprecedented acceleration of the clinical testing process.

Typically, testing and approving a new vaccine takes two or three years. Sometimes more. But under the federal government’s Operation Warp Speed, Modena received a fast-track designation from the Food and Drug Administration. It also got a $483 million award to further its Covid-19 vaccine.

Through its Coronavirus Vaccine Tracker The Times is updating the status of all the vaccines that have reached human testing, along with a selection of promising vaccines still being tested in cells or animals. Because of the number and especially speed at which bioscience and pharmaceutical firms are moving to develop a successful vaccine, the Tracker is being updated almost every day.

The World Health Organization lists 149 different vaccine projects underway worldwide. 17 are in clinical evaluation, meaning they are being tested in humans, either in small groups to ensure their safety and basic efficacy, or in hundreds to see the effect among different age groups.

The Vaccine Tracker lists five vaccine candidates that are in or about to launch Phase III testing, the broadest testing category where thousands of volunteers are enlisted to determine if the vaccine is widely effective and how well it protects people from becoming infected. That’s the test Moderna expects to begin soon.

A vaccine developed by AstraZeneca and the University of Oxford is already in Phase III testing in Brazil and South Africa and is in a simultaneous Phase II and III study in Europe. This program, like Moderna’s, is part of Operation Warp Speed.

The Vaccine Tracker lists two Chinese firms – Sinovac Biotech and Sinopharm – as ready to soon start broad testing of their respective vaccines. Sinopharm’s testing will be conducted in the United Arab Emirates. Sinovac plans to conduct its Phase III study in China and Brazil.

A fifth vaccine, which is not a vaccine specifically for COVID-19, but a sort of immune system booster, is being tested in Australia. Bacillus Calmette-Guerin, a vaccine originally developed for tuberculosis, has been found over its 100 year history to help fight off other types of infections and parasites. The Phase III testing will determine if it also helps protect against COVID-19.

Image by Angelo Esslinger

Marketing Strategies: 2024 Trends and Strategies for Success
General Interest

Marketing Strategies: 2024 Trends and Strategies for Success

The Essence of Marketing Strategy: Driving Business Success (Part II)
General Interest

The Essence of Marketing Strategy: Driving Business Success (Part II)

The Essence of Marketing Strategy: Driving Business Success
General Interest

The Essence of Marketing Strategy: Driving Business Success

Mastering Task Prioritization for Stress Reduction
General Interest

Mastering Task Prioritization for Stress Reduction

Crafting the Future: Delving into AI as a College Major
General Interest Information Technology

Crafting the Future: Delving into AI as a College Major

Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team
General Interest Pharma

Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team

Leveraging LinkedIn Polls: A Strategic Tool for Business Insights
General Interest

Leveraging LinkedIn Polls: A Strategic Tool for Business Insights

#WeAreGreenKey: Spotlight on Kyle Gierke
General Interest Healthcare

#WeAreGreenKey: Spotlight on Kyle Gierke

Essential Strategies for 2024: Remote Training
General Interest

Essential Strategies for 2024: Remote Training

Steps to Nurture a Multigenerational Workforce
General Interest

Steps to Nurture a Multigenerational Workforce

Tips to Cultivate a Compelling Employer Brand
General Interest

Tips to Cultivate a Compelling Employer Brand

Green Key Names 3 New Partners in 2024
General Interest

Green Key Names 3 New Partners in 2024

#WeAreGreenKey: Spotlight on Samantha Desena 
Accounting + Finance General Interest

#WeAreGreenKey: Spotlight on Samantha Desena 

Why Companies are Already Recruiting Interns for 2025
General Interest

Why Companies are Already Recruiting Interns for 2025

Todd Gabianelli Selected as an Old Master at Purdue University 
Pharma

Todd Gabianelli Selected as an Old Master at Purdue University 

Navigating the Surge of Respiratory Illnesses Across the U.S.
General Interest

Navigating the Surge of Respiratory Illnesses Across the U.S.

Gen Z: Catalysts for Workplace Evolution in 2024
General Interest

Gen Z: Catalysts for Workplace Evolution in 2024

The Office Real Estate Dilemma
General Interest

The Office Real Estate Dilemma

#WeAreGreenKey: Spotlight on Rich Egloff
Architecture + Engineering Leadership + Management

#WeAreGreenKey: Spotlight on Rich Egloff

From the Big Quit to the Big Stay
General Interest

From the Big Quit to the Big Stay

Latest Blog Posts
View All Posts
Marketing Strategies: 2024 Trends and Strategies for Success

Marketing Strategies: 2024 Trends and Strategies for Success

In our last two articles, we delved into marketing strategies, uncovering what they are, the multiple types, how they work,...
Read More
The Essence of Marketing Strategy: Driving Business Success (Part II)

The Essence of Marketing Strategy: Driving Business Success (Part II)

With a grasp of the fundamental concept of Marketing Strategy, let’s explore its advantages in more detail and uncover the...
Read More
The Essence of Marketing Strategy: Driving Business Success

The Essence of Marketing Strategy: Driving Business Success

In the intricate world of business, a marketing strategy serves as the cornerstone upon which companies build their path to...
Read More